The global C-reactive protein testing market was valued at USD 5.3 billion in 2025 and is estimated to reach USD 5.4 billion in 2026. The market is projected to grow to USD 6.1 billion by 2033, expanding at a CAGR of 1.7% from 2026 to 2033. This steady growth is being supported by the increasing burden of cardiovascular diseases, diabetes, autoimmune conditions, infections, and other inflammatory disorders. CRP testing is an important diagnostic tool because elevated C-reactive protein levels can indicate inflammation and help healthcare professionals assess disease activity and support timely clinical decisions. The growing emphasis on precision medicine, preventive healthcare, and accessible diagnostic testing is further strengthening market demand.

Download a free sample copy of the C-Reactive Protein Testing Market report to understand detailed coverage and inclusions in the final report 

Market Segments and Breakdown

• Assay Types: Immunoturbidimetric assays accounted for the largest share of the market at 48.4% in 2025. These assays are widely used because they support rapid, automated, and quantitative CRP measurement. ELISA is another established testing method, while continued advances in immunoassay technologies are improving sensitivity, automation, and laboratory efficiency.

• Detection Range: The hs-CRP segment held the largest share of 62.0% in 2025. High-sensitivity CRP testing is increasingly important for evaluating low levels of inflammation and assessing cardiovascular risk. Its application in preventive healthcare and cardiovascular disease management is contributing to wider adoption.

• Disease Area: The rheumatoid arthritis segment accounted for 25.7% of the market in 2025, representing the leading disease-area application. CRP measurements can help clinicians monitor inflammatory activity and evaluate treatment response in patients with rheumatoid arthritis and other inflammatory conditions. Cardiovascular diseases also represent an important application area as healthcare providers increasingly use hs-CRP measurements in risk assessment.

• End-use Settings: Hospitals held the largest share of 38.1% in 2025. Hospitals use CRP testing extensively for diagnosing and monitoring infections, inflammatory diseases, cardiovascular conditions, and other medical conditions. Diagnostic laboratories and other healthcare facilities also contribute significantly to market demand.

Core Market Drivers

• Rising Chronic Disease Burden: The growing prevalence of cardiovascular disorders, diabetes, autoimmune diseases, and inflammatory conditions is increasing the need for diagnostic and monitoring tools. CRP testing provides clinicians with an important biomarker for identifying and monitoring inflammation.

• Point-of-Care Testing: The development of point-of-care CRP testing is making diagnostic services faster and more accessible. Portable systems can deliver results in clinics, pharmacies, primary healthcare settings, and potentially home-care environments, reducing turnaround times and supporting faster treatment decisions.

• Growing Focus on Preventive Healthcare: Increasing awareness of early disease detection is encouraging patients and healthcare providers to use diagnostic tests as part of routine health assessments. CRP testing can support the identification of inflammation before conditions progress into more serious complications.

• Expansion of Personalized Medicine: The increasing adoption of personalized healthcare is creating opportunities for biomarker-based diagnostics. CRP measurements can contribute to individualized risk assessment and treatment strategies, particularly in cardiovascular and inflammatory diseases.

Technological Advancements

Technological innovation is transforming the way CRP testing is performed. Traditional laboratory-based testing is increasingly being complemented by portable, rapid, and automated diagnostic platforms. Improvements in assay sensitivity, automation, and testing accessibility are helping healthcare professionals obtain reliable results more efficiently.

Point-of-care technologies are particularly important because they allow testing to be performed closer to the patient. The development of electrochemical sensors, microfluidic systems, and wearable technologies could further expand the role of CRP monitoring. Grand View Research highlights research into minimally invasive microneedle-array systems capable of detecting CRP in interstitial fluid, creating possibilities for wearable and continuous monitoring applications.

Advances in immunoturbidimetric assays are also supporting market development. Latex-enhanced approaches and nanoparticle-enhanced immunoturbidimetric assays can improve sensitivity and enable high-throughput analysis. Such developments are particularly relevant to hospitals and large diagnostic laboratories where efficient processing of high test volumes is important.

Growing Importance of Cardiovascular Applications

Cardiovascular disease is emerging as an important area for CRP testing, particularly through high-sensitivity CRP measurements. hs-CRP can help evaluate low-grade inflammation associated with cardiovascular risk, making it increasingly relevant to preventive health strategies.

The growing interest in earlier cardiovascular risk assessment is encouraging researchers and healthcare organizations to investigate the broader clinical applications of hs-CRP. Research highlighted by Grand View Research has explored hsCRP measurements for evaluating cardiovascular risks in women, emphasizing the potential role of inflammatory biomarkers in personalized healthcare.

Emerging Market Opportunities

Emerging economies represent an important opportunity for CRP testing companies. Urbanization, changing lifestyles, aging populations, and increasing rates of chronic diseases are expanding the need for accessible diagnostic services. At the same time, healthcare infrastructure and diagnostic laboratory networks are expanding across developing markets.

Point-of-care CRP testing can be particularly valuable in rural and underserved areas because it reduces dependence on centralized laboratories and enables faster clinical decision-making. The availability of affordable testing devices could therefore support wider adoption in low- and middle-income countries.

Looking for more specific insights? Customize this report to suite your business needs

Regional Market Outlook

• North America: North America dominated the global market with a 40.9% revenue share in 2025. The region benefits from advanced healthcare infrastructure, high adoption of diagnostic technologies, strong research activity, and growing demand for precision medicine. The U.S. held the largest country-level market share in 2025.

• Asia Pacific: Asia Pacific is expected to register the fastest CAGR from 2026 to 2033. Rising healthcare expenditure, expanding diagnostic infrastructure, increasing chronic disease prevalence, and growing accessibility of point-of-care technologies are creating significant opportunities across the region.

• Europe: European markets are supported by established healthcare systems, preventive healthcare initiatives, and increasing attention toward appropriate antibiotic use. CRP testing can help clinicians distinguish between conditions requiring different treatment approaches, supporting demand for rapid diagnostic solutions.

• Latin America, Middle East & Africa: Improving healthcare infrastructure and the expansion of diagnostic services are expected to create additional opportunities. Affordable and portable CRP testing platforms could be particularly useful in areas where centralized laboratory access remains limited.

Competitive Landscape

The global C-reactive protein testing market features established diagnostic companies competing through technological innovation, product development, strategic partnerships, and research and development. Key companies include:

• Abbott Laboratories

• Beckman Coulter, Inc. (Danaher Corporation)

• F. Hoffmann-La Roche AG

• Laboratory Corporation of America Holdings

• Siemens Healthineers

• Thermo Fisher Scientific Inc.

• QuidelOrtho Corporation

• HORIBA, Ltd.

• DiaSys Diagnostic Systems GmbH

• Randox Laboratories Ltd.

These companies are focusing on improving assay accuracy, automation, sensitivity, turnaround time, and accessibility. Strategic collaborations involving diagnostic, pharmaceutical, biotechnology, and clinical research organizations are also helping expand the applications of CRP testing.

Future Outlook

The global C-reactive protein testing market is projected to reach USD 6.1 billion by 2033, growing at a CAGR of 1.7% from 2026 to 2033. While overall market expansion is moderate, continued innovation in point-of-care diagnostics, high-sensitivity assays, wearable technologies, and personalized medicine is expected to create new growth opportunities.

The increasing burden of chronic and inflammatory diseases, greater emphasis on preventive healthcare, and demand for rapid diagnostic decision-making will remain important market drivers. At the same time, emerging economies are likely to offer attractive opportunities as healthcare systems expand and affordable diagnostic technologies become more widely available. As CRP testing moves beyond conventional laboratory settings toward portable and potentially wearable platforms, the technology is expected to become an increasingly accessible component of modern disease screening, monitoring, and personalized healthcare.